Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVGRNASDAQ:HSDTNASDAQ:NDRANYSE:SONX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$4.15$1.57M1.091.03 million shsN/AHSDTHelius Medical Technologies$0.29-3.0%$0.40$0.26▼$4.85$1.76M1.271.38 million shs83,369 shsNDRAENDRA Life Sciences$3.98+15.4%$4.03$2.97▼$664.83$2.24M0.19127,809 shs636,121 shsSONXSonendo$1.14$1.67$1.00▼$21.98$488K1.381,154 shs53 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%-19.52%-87.19%HSDTHelius Medical Technologies+2.37%+9.82%-26.63%-55.91%-93.66%NDRAENDRA Life Sciences-8.73%-5.99%-19.77%-38.72%-99.98%SONXSonendo0.00%-8.06%-32.94%-59.75%+1,117.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVGRAvingerN/AN/AN/AN/AN/AN/AN/AN/AHSDTHelius Medical TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ANDRAENDRA Life Sciences2.4948 of 5 stars3.54.00.00.01.90.01.3SONXSonendoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger 0.00N/AN/AN/AHSDTHelius Medical Technologies 2.00HoldN/AN/ANDRAENDRA Life Sciences 3.00Buy$50.001,156.28% UpsideSONXSonendo 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SONX, HSDT, NDRA, and AVGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025NDRAENDRA Life SciencesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $50.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.26M0.22N/AN/A($4.53) per share-0.10HSDTHelius Medical Technologies$520K3.38N/AN/A$3.32 per share0.09NDRAENDRA Life SciencesN/AN/AN/AN/A$1,170.18 per shareN/ASONXSonendo$44.40M0.01N/AN/A$89.42 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$11.06N/AN/AN/A-261.06%-5,527.11%-123.25%5/13/2025 (Estimated)HSDTHelius Medical Technologies-$8.85M-$5.74N/A∞N/A-1,764.74%-244.82%-127.10%5/12/2025 (Estimated)NDRAENDRA Life Sciences-$10.06M-$624.72N/AN/AN/AN/A-127.39%-103.77%5/13/2025 (Estimated)SONXSonendo-$60.92M-$59.12N/A∞N/A-92.74%-184.01%-68.60%6/10/2025 (Estimated)Latest SONX, HSDT, NDRA, and AVGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NDRAENDRA Life Sciences-$4.08N/AN/AN/AN/AN/A5/12/2025Q1 2025HSDTHelius Medical Technologies-$0.92N/AN/AN/A$0.10 millionN/A3/31/2025Q4 2024NDRAENDRA Life Sciences-$4.10-$9.40-$5.30-$20.78N/AN/A3/25/2025Q4 2024HSDTHelius Medical Technologies-$0.94-$1.03-$0.09-$1.03$0.10 million$0.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/AHSDTHelius Medical TechnologiesN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ASONXSonendoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/A1.210.81HSDTHelius Medical TechnologiesN/A3.613.10NDRAENDRA Life SciencesN/A6.106.10SONXSonendo0.551.821.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%HSDTHelius Medical Technologies18.63%NDRAENDRA Life Sciences1.19%SONXSonendo28.68%Insider OwnershipCompanyInsider OwnershipAVGRAvinger42.80%HSDTHelius Medical Technologies5.10%NDRAENDRA Life Sciences0.04%SONXSonendo7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger703.31 million1.89 millionNot OptionableHSDTHelius Medical Technologies306.13 million3.54 millionNot OptionableNDRAENDRA Life Sciences20562,000537,000Not OptionableSONXSonendo250428,000393,000Not OptionableSONX, HSDT, NDRA, and AVGR HeadlinesRecent News About These CompaniesSonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | businesswire.comSonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024November 11, 2024 | businesswire.comSonendo, Inc. (SONX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseNovember 5, 2024 | zacks.comSonendo Launches ProControlTM for the GentleWave® G4 SystemOctober 23, 2024 | businesswire.comSonendo, Inc. Announces Preliminary Third Quarter 2024 Financial ResultsOctober 10, 2024 | businesswire.comBIOLASE files for Chapter 11, plans asset sale to SonendoOctober 3, 2024 | investing.comHere's Why Sonendo (SONX) Is a Great 'Buy the Bottom' Stock NowAugust 27, 2024 | zacks.comSonendo Inc.August 17, 2024 | marketwatch.comSonendo, Inc. (SONX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comSonendo, Inc. (SONX) Reports Q2 Loss, Tops Revenue EstimatesAugust 7, 2024 | zacks.comSonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue GuidanceAugust 7, 2024 | finance.yahoo.comHere's what Wall Street expects from Sonendo's earnings reportAugust 7, 2024 | markets.businessinsider.comSonendo, Inc. (SONX)July 28, 2024 | finance.yahoo.comSonendo Strengthens Leadership With Key Strategic AppointmentsJune 5, 2024 | businesswire.comSonendo to Present at the 2024 Stifel Jaws & Paws ConferenceMay 20, 2024 | businesswire.comSonendo, Inc. (SONX) Q1 2024 Earnings Call TranscriptMay 12, 2024 | seekingalpha.comSonendo, Inc. (NYSE:SONX) Q1 2024 Earnings Call TranscriptMay 12, 2024 | msn.comSonendo Inc (SONX) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and Financial ...May 9, 2024 | finance.yahoo.comSONX Stock Earnings: Sonendo Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | investorplace.comSonendo, Inc. Reports First Quarter 2024 Financial Results and Announces Strategic Reset PrioritiesMay 8, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSONX, HSDT, NDRA, and AVGR Company DescriptionsAvinger NASDAQ:AVGR$0.47 0.00 (0.00%) As of 04/24/2025Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Helius Medical Technologies NASDAQ:HSDT$0.29 -0.01 (-3.04%) Closing price 03:58 PM EasternExtended Trading$0.30 +0.01 (+2.79%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.ENDRA Life Sciences NASDAQ:NDRA$3.98 +0.53 (+15.36%) Closing price 04:00 PM EasternExtended Trading$3.77 -0.21 (-5.28%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Sonendo NYSE:SONX$1.14 0.00 (0.00%) As of 04/24/2025Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment, a technology platform designed for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid EDTA that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software to enable an integrated digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. The company was incorporated in 2006 and is headquartered in Laguna Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
